Angiography, Hyperaldosteronism
Conditions
Keywords
Adrenal venous sampling, Hyperaldosteronism, Angiography, Antecubital approach
Brief summary
Currently, adrenal venous sampling (AVS) serves as the gold standard for subtyping of PA. Right adrenal vein catheterization is often difficult due to unfavorable anatomy of the vein including small vein size, short length, caudal direction for the transfemoral approach, and rare drainage to the accessory hepatic vein. All of these factors limit the widespread use of this approach. Given that the right adrenal vein is angled caudally in most patients, AVS via an antecubital approach was performed since January 2012. The purpose of this multicenter retrospective study was to evaluate the safety and feasibility of AVS via the antecubital approach.
Detailed description
Primary aldosteronism (PA) is recognized as the most common cause of secondary hypertension, with a prevalence of approximately 10% among unselected hypertensive populations. Subtype diagnosis is crucial because unilateral primary aldosteronism can be treated by laparoscopic adrenalectomy or open surgery, which may result in a cure or significant improvement of blood pressure, thus decreases the incidence of cardio-cerebrovascular complications. Currently, adrenal venous sampling (AVS) serves as the gold standard for subtyping of PA. Given that the right adrenal vein is angled caudally in most patients, AVS via an antecubital approach was performed since January 2012 at the Fuwai Hospital. So far, there have been more than fifteen hospitals to have some experience on AVS via antecubital approach with investigators' helps. The purpose of this multicenter retrospective study was to evaluate the safety and feasibility of AVS via the antecubital approach.
Interventions
Adrenal Venous Sampling via an Antecubital Approach
Sponsors
Study design
Eligibility
Inclusion criteria
* Consent of the principal investigator to participate to the data collection of patients with primary aldosteronism underwent AVS via antecubital approach
Exclusion criteria
* Refusal of the principal investigator to participate to the AVSA Study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The success rate of bilateral adrenal sampling | From January 1st 2012 to December 31st 2018 |
Secondary
| Measure | Time frame |
|---|---|
| The success rate of right adrenal sampling | From January 1st 2012 to December 31st 2018 |
| The success rate of left adrenal sampling | From January 1st 2012 to December 31st 2018 |
| The incidence of adrenal vein ruptures occurring during AVS | From January 1st 2012 to December 31st 2018 |
Countries
China